Tibet Weixinkang Pharmaceutical announced that its wholly-owned subsidiary, Tibet Weixinkang, has received the "Drug Clinical Trial Approval Notice" for Deoxycholic Acid Injection issued by the National Medical Products Administration. This drug is used to improve the contour elevation or facial overfullness caused by moderate to severe submental fat accumulation in adults, and it has not yet been approved for marketing in China.
卫信康：子公司获去氧胆酸注射液临床试验批准
Tibet Weixinkang Pharmaceutical: Subsidiary approved for clinical trial of deoxycholic acid injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.